Myrtelle’s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Innovative Licensing and Access Pathway Designation from the UK Medicines and Healthcare Products Regulatory Agency
Wakefield, Mass., April 25th, 2023- Myrtelle Inc., (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Article Date
April 25, 2023
This article is featured on another website.
Go to article
June 17, 2026
BioHub podcast with Sean A. MacDonald, CEO at Kainova Therapeutics
June 17, 2026
BioHub podcast with Sean A. MacDonald, CEO at Kainova Therapeutics
July 15, 2026
Glioblastoma Clinical Trials – Where Progress is Actually Happening in Glioma Research
Where Glioma Research Is Actually Moving Forward Glioblastoma (GBM) is the most common and most…
July 15, 2026
Glioblastoma Clinical Trials – Where Progress is Actually Happening in Glioma Research
Where Glioma Research Is Actually Moving Forward Glioblastoma (GBM) is the most common and most…